| abstract |
The disclosure relates to HCV proteins in which cysteine residues are reversibly protected during purification. Eventually, this purification procedure results in HCV proteins with biological activity and a native-like protein conformation, which present corresponding epitopes. Disclosed also are drug screening methods using these HCV proteins, and diagnostic and therapeutic applications, such as vaccines and drugs. |